EBT-105

N/A

Report date: 2025/08/20 16:52:42

Base Information

Drug NameEBT-105
Drug Alias NameAAV-delivered CRISPR/CasY nuclease gene editing therapy (Excision BioTherapeutics)EBT-105
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPRCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionHSV replication inhibitors
TargetsUpdating
Therapy Area/IndicationsHerpes Simplex Virus Type 2 Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesExcision BioTherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesExcision BioTherapeutics Inc
Inactive CompaniesN/A
Active IndicationsHerpes Simplex Virus Type 2 Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A